Skip to main content

Treatment Clinical Trials for Merkel Cell Cancer

Review the Merkel cell cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Testing the Combination of two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Status: Active
Location: 51 locations
Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Status: Active
Location: 25 locations
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Status: Active
Location: 9 locations
A Study of CRD3874-SI in People With Locally Advanced or Metastatic Malignant Solid Tumor
Status: Active
Location: 7 locations
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
Status: Active
Location: 6 locations
A Study of DF6002 Alone and in Combination With Nivolumab
Status: Active
Location: 5 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 3 locations
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Status: Active
Location: 2 locations
In Situ Immunomodulation for Unresectable and Metastatic Solid Tumors
Status: Active
Location: 2 locations
Hypofractionated Radiation Therapy for the Treatment of Merkel Cell Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Pembrolizumab for Treatment of Resectable Stage I-III Merkel Cell Carcinoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Cytotoxic T Lymphocytes in Treating Patients with Malignancies with BK and/or JC Virus
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Status: Active
Location: See ClinicalTrials.gov
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas